natural glp-1 agonists receptor and next-generation metabolic hormone therapies in chronic kidney disease Mapping the effectiveness and risks

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide in non-diabetic patients with obesity and prior cardiovascular events [4,5]

As a result, NASH resolution has become one of the main outcomes of clinical studies of MAFLD, apart from liver fibrosis regression

4.2 Promotion of insulin secretion GLP-1 stimulates insulin secretion in a glucose-dependent manner through specific receptors expressed on pancreatic cells.GLP-1R is a family of secretins (class B) that couples GLP-1 to downstream cell responses, and conformational changes in the receptor upon ligand binding facilitate the interaction between its intracellular region and signaling proteins (Jones et al., 2018)

In T1D, miR-192 is elevated and controls pancreatic -cell growth by regulating cell proliferation and apoptosis, ultimately reducing insulin release

Al-SadawiMAAslamFMTaoMAlsaiqaliMAlmasryIOFanRet alEffects of GLP-1 agonists on mortality and arrhythmias in patients with type II diabetes

To compensate, retatrutide establishes GCGR-specific interactions including stacking with F33 ECD (via F22 P ) and Y138 1.36b (via F6 P ), and three hydrogen bonds with Q142 1.40b (via Y10 P ), Q293 ECL2 (via D15 P ) and Q374 ECL3 (via D9 P )